Mumbai, Aug 27: Pharma major, Cipla said that it has received six observations from the USFDA following the inspection conducted in August 2022 at its Goa plant.
Company said Goa plant recently underwent a United States Food and Drug Administration (USFDA) inspection from August 16 to 26, 2022. Earlier, The USFDA had inspected the company’s Goa manufacturing facility in September 2019. A warning letter for the same was received by the company in February 2020. Company further informed that on conclusion of the inspection, the company has now received 6 observations with some referencing to the observations made during the September 2019 inspection. There are no data integrity observations. “The company will work closely with the US FDA and is committed to address these within the stipulated time, Company said in a filing with BSE. (UNI)
Follow our WhatsApp channel
